Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses

Journal of Infectious Diseases

Volumn 204, Issue 3, 2011, Pages 377-384

  Westra, Tjalke A ^a   Rozenbaum, Mark H ^b   Rogoza, Raina M ^c   Nijman, Hans W ^a   Daemen, Toos ^a   Postma, Maarten J ^a,b   Wilschut, Jan C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Unit of PharmacoEpidemiology and PharmacoEconomics (FE2)   (Netherlands)

^c Health Economics and Outcomes Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; AGE DETERMINATION; ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 79960123228     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir281     Document Type: Article

References (40)

1. http://www.emea.europa.eu/. Accessed 1 September 2010.
2. Medeiros LR, Rosa DD, da Rosa MI, et al. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer 2009; 19:1166-76.
3. Arbyn M, Raifu AO, Autier P, et al. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007; 18:1708-15.
4. Levy-Bruhl D, Bousquet V, King LA, et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur J Cancer 2009; 45:2709-13.
5. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24.
6. Weisberg E, Bateson D, McCaffery K, et al. HPV vaccination catch up program - utilisation by young Australian women. Aust Fam Physician 2009; 38:72-6.
7. Simoens C, Sabbe M, Van Damme P, et al. Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Euro Surveill 2009; 14(46).
8. Brabin L, Roberts SA, Stretch R, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008; 336:1056-8. (Pubitemid 351692248)
9. Rondy M, van Lier A, van de Kassteele J, et al. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 2010; 28:2070-5.
10. Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010; 102:933-9.
11. Munoz N, Manalastas R Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-57.
12. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27:581-7.
13. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705-19.
14. Smith JS, Melendy A, Rana RK, et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43:S5-25, S25. e1-41.
15. Markowitz LE. HPV vaccines prophylactic, not therapeutic. JAMA 2007; 298:805-6. (Pubitemid 47263164)
16. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55.
17. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102:325-39.
18. Steben M. Update on Gardasil (R) (quadrivalent human papillomavirus [HPV] 6/11/16/18 vaccine) clinical trial efficacy results. In: Presented at EUROGIN 2010, Monte Carlo, Monaco, 17-20 February Abstract available at: http://www,eurogin.com/2010/EUROGIN2010-Abstracts.pdf. 2010:106.
19. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769.
20. Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009; 27:4776-83.
21. Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 2008; 26(Suppl 5):F46-58.
22. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007; 96:143-50. (Pubitemid 46094653)
23. Jacobs MMV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000; 87:221-7. (Pubitemid 30434349)
24. Dutch cancer registration. http://www.ikcnet.nl. Accessed 1 March 2010.
25. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2:868-78.
26. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85.
27. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
28. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009; 27(Suppl 1):A46-53.
29. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-35.
30. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
31. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009; 115:S1-6.
32. de Graaff M. CFH-rapport Cervarix. 2008. http://www.cvz.nl. Accessed 1 March 2010.
33. Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010; 340:c2509.
34. Raad voor de Volksgezondheid en Zorg. Zinnige en duurzame zorg. http://www.rvz.net report 2006:7.
35. Westra TA, Daemen T, Postma MJ, et al. Efficiency of human papillomavirus vaccination-estimates based on Dutch cost effectiveness analyses. Ned Tijdschr Geneeskd 2009; 153:A356.
36. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5:696-704.
37. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12:343-51.
38. de Peuter MA, Littlewood KJ, Annemans L, et al. Cost-effectiveness of catch-up programs in human papillomavirus vaccination. Expert Rev Vaccines 2010; 9:1187-201.
39. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32.
40. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151:538-45.